FABP3

Summary

FABP3 (fatty acid binding protein 3, HGNC:3557) is a protein-coding gene on chromosome 1p35.2, encoding Fatty acid-binding protein, heart (P05413). FABPs are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters.

The intracellular fatty acid-binding proteins (FABPs) belongs to a multigene family. FABPs are divided into at least three distinct types, namely the hepatic-, intestinal- and cardiac-type. They form 14-15 kDa proteins and are thought to participate in the uptake, intracellular metabolism and/or transport of long-chain fatty acids. They may also be responsible in the modulation of cell growth and proliferation. Fatty acid-binding protein 3 gene contains four exons and its function is to arrest growth of mammary epithelial cells. This gene is a candidate tumor suppressor gene for human breast cancer. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 2170 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 41 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_004102

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3557
Approved symbol	FABP3
Name	fatty acid binding protein 3
Location	1p35.2
Locus type	gene with protein product
Status	Approved
Aliases	H-FABP, O-FABP
Ensembl gene	ENSG00000121769
Ensembl biotype	protein_coding
OMIM	134651
Entrez	2170

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000373713, ENST00000482018, ENST00000497275, ENST00000498148, ENST00000864321, ENST00000864322, ENST00000915558, ENST00000915559, ENST00000970076, ENST00000970077

RefSeq mRNA: 2 — MANE Select: NM_004102 NM_001320996, NM_004102

CCDS: CCDS342

Canonical transcript exons

ENST00000373713 — 4 exons

Exon	Start	End
ENSE00001178232	31372942	31373076
ENSE00001461361	31365253	31365939
ENSE00003503829	31369385	31369557
ENSE00003655704	31367393	31367494

Expression profiles

Bgee: expression breadth ubiquitous, 247 present calls, max score 99.91.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 72.0935 / max 6921.3988, expressed in 1087 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
11463	70.8532	1085
11462	1.1566	371
201445	0.0837	41

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
apex of heart	UBERON:0002098	99.91	gold quality
right atrium auricular region	UBERON:0006631	99.91	gold quality
cardiac atrium	UBERON:0002081	99.83	gold quality
heart left ventricle	UBERON:0002084	99.80	gold quality
cardiac ventricle	UBERON:0002082	99.79	gold quality
hindlimb stylopod muscle	UBERON:0004252	99.72	gold quality
heart right ventricle	UBERON:0002080	99.62	gold quality
gastrocnemius	UBERON:0001388	99.57	gold quality
left ventricle myocardium	UBERON:0006566	99.38	gold quality
heart	UBERON:0000948	99.37	gold quality
myocardium	UBERON:0002349	99.18	gold quality
muscle of leg	UBERON:0001383	99.13	gold quality
vena cava	UBERON:0004087	98.69	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.65	gold quality
right coronary artery	UBERON:0001625	98.42	gold quality
diaphragm	UBERON:0001103	98.23	gold quality
triceps brachii	UBERON:0001509	98.22	gold quality
muscle organ	UBERON:0001630	98.10	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.09	gold quality
right frontal lobe	UBERON:0002810	98.03	gold quality
biceps brachii	UBERON:0001507	97.93	gold quality
body of tongue	UBERON:0011876	97.82	gold quality
skeletal muscle tissue	UBERON:0001134	97.49	gold quality
popliteal artery	UBERON:0002250	97.46	gold quality
tibial artery	UBERON:0007610	97.45	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	97.21	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	97.06	gold quality
prefrontal cortex	UBERON:0000451	96.87	gold quality
muscle tissue	UBERON:0002385	96.65	gold quality
left coronary artery	UBERON:0001626	96.60	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-10885	yes	5907.91
E-MTAB-9841	yes	3955.69
E-HCAD-10	yes	11.85
E-ANND-3	yes	9.66
E-MTAB-7316	yes	8.68
E-MTAB-10855	no	3161.12
E-MTAB-3929	no	840.75
E-HCAD-38	no	347.02

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FLCN, FOXA2, PPARA, PPARG

miRNA regulators (miRDB)

26 targeting FABP3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-548AN	99.97	70.91	2817
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-3663-3P	99.84	70.39	798
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-1825	99.72	68.11	1089
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-7150	99.62	66.80	1322
HSA-MIR-497-3P	99.61	69.71	1990
HSA-MIR-6871-3P	99.43	68.85	741
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-8077	99.17	66.67	862
HSA-MIR-143-5P	98.98	68.87	946
HSA-MIR-4724-5P	98.87	67.75	1324
HSA-MIR-6889-3P	98.84	67.35	1198
HSA-MIR-760	98.81	66.65	1392
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-2467-3P	98.65	67.18	1969
HSA-MIR-6847-5P	97.93	66.74	1808
HSA-MIR-8057	97.64	66.54	897
HSA-MIR-6730-3P	97.03	67.54	889
HSA-MIR-301A-5P	96.88	68.07	931
HSA-MIR-301B-5P	96.88	67.75	946
HSA-MIR-2861	95.24	65.47	1056

Literature-anchored findings (GeneRIF, showing 40)

• Decreased heart-type FABP levels may alter lipid composition and/or fluidity in membrane of brains with degeneration, e.g., Down syndrome and Alzheimer’s disease. (PMID:15068254)
• A subset of human gastric carcinoma expresses H-FABP and its expression is associated with FAS status, disease progression, tumor aggressiveness and poor patient survival. (PMID:15459486)
• heart-type fatty acid-binding protein affects the response to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma (PMID:17289870)
• H-FABP may play a key role in the progress of invasiveness and metastasis in human breast cancer. (PMID:17428383)
• high serum H-FABP levels may represent latent cardiac injury and have important clinical implications (PMID:17721027)
• Hypoxia enhances the expression of FABP3 in term human trophoblasts, suggesting that fatty acid binding proteins support fat accumulation in the hypoxic placenta. (PMID:17826730)
• FABP3 predicts long-term mortality after ACS and identifies high-risk patients in a manner that is additive to clinical risk factors, troponin, and hs-CRP, possibly identifying myocardial ischemia with or without necrosis. (PMID:18021874)
• persistently high H-FABP levels despite improvement in symptoms and signs of CHF predicted significantly higher cardiac event rates (PMID:18159110)
• patients with baseline heart-type fatty acid-binding protein (H-FABP) concentrations >2.7 ng x mL(-1), the median value of the biomarker in the surgically treated population, had a lower probability of event-free survival after pulmonary endarterectomy (PMID:18256058)
• This study is the first to assess the diagnostic value of H-FABP for acute myocardial infarction outside a hospital-setting. (PMID:18412949)
• We found an association between FABP3 gene polymorphisms and EH in a Japanese population, thereby suggesting that FABP3 is a susceptibility locus for EH. (PMID:18437121)
• H-FABP (heart-type fatty acid binding protein ) is a sensitive diagnostic biochemical marker of Acute Coronary Syndrome, particularly within the first 6 h of symptoms, in patients attending the emergency department. (PMID:18460953)
• Identification of two previously unreported SNPs in FGFR1 and FABP3 associated with BMD and a third SNP in TIMP2 related to risk for non-vertebral osteoporotic fractures. (PMID:18469019)
• Results of H-FABP immunotest give a better diagnostic classification than cardiac troponin I at the early stage of acute myocardial infarction (AMI) in patients presenting to the Emergency Department suspected of AMI. (PMID:18571749)
• Heart-type fatty acid-binding protein significantly increases after elective coronary angioplasty at 1 h compared with baseline values (PMID:19552571)
• brain-expressed fatty-acid binding protein (FABP) genes 3, 5 and 7 may have roles in schizophrenia and bipolar disorder (PMID:19554614)
• Serum H-FABP and leptin increased simultaneously and significantly in the patients, and leptin alleviated pulmonary and intestinal injuries by restraining tissue H-FABP secretions in the mouse model of sepsis (PMID:19576209)
• Serum H-FABP levels were significantly higher in patients with diabetic MetS than in without diabetic MetS, 24.0 +/- 10.2 and 13.9 +/- 12.6 ng/ml, respectively. (PMID:19806479)
• H-FABP could be soon introduced in clinical practice in combination with well-established markers like troponins (PMID:20391015)
• Compared with traditional markers of myocardial injury after coronary artery bypass grafting, hFABP peaks earlier and is a superior independent predictor of postoperative mortality and ventricular dysfunction. (PMID:20457766)
• Studies indicate that three of the ten mammalian FABPs identified to date (FABP3, FABP5, FABP7) are expressed in the brain. (PMID:20563994)
• Heart-type fatty acid-binding protein is significantly associated with right ventricular dysfunction and predicts mortality in patients with pulmonary embolism at intermediate risk. (PMID:20691835)
• h-FABP may be an early parameter for monitoring radiofrequency ablation-induced lesions and the site of ablation was relevant for biomarker increase. (PMID:20709047)
• This review identifies a novel binding protein, heart-type fatty acid-binding protein which interacts with domapine D2 receptor. (PMID:20716856)
• FABP-3 binds directly to the cytoplasmic tail of integrin alpha-subunits and its expression inhibits integrin activity, resulting in inhiibition of cell invasion. (PMID:20802519)
• Data show that patients with acromegaly have increased levels of H-FABP, and suggest that serum H-FABP levels might be a marker of myocardial performance in patients with acromegaly. (PMID:20834198)
• HFABP levels were higher in Alzheimer (AD) patients and in Mild Cognitive Impairment converting to AD (MCI-AD) with respect to other neurological disorders and to cognitively stable MCI patients (MCI-MCI). (PMID:20930282)
• In contrast to heart-type FABP, serum levels of brain-type FABP are elevated in a significant proportion of patients with various neurodegenerative diseases. (PMID:21143341)
• Urinary NAG (ninefold), NGAL (1.5-fold), and H-FABP (3.5-fold) were significantly elevated in normoalbuminuric diabetic patients compared with nondiabetic control subjects. (PMID:21307379)
• H-FABP may represent a marker for early carotid atherosclerosis in prediabetic patients. (PMID:21535886)
• H-FABP could serve as a new monitoring tool to provide information that will guide the optimal therapy and management of CHD patients. (PMID:21617322)
• Levels of highly sensitive troponin T and heart fatty acid binding protein are significantly higher in patients with asymptomatic left ventricular diastolic function and heart failure patients with normal ejection fraction, compared to controls. (PMID:21729325)
• H-FABP offers similar overall diagnostic performance, while the combination of H-FABP and MPO assays may improve the diagnosis of ACS, particularly in patients with recent onset of chest pain. (PMID:21937835)
• Measurement of h-FABP was insufficient to be used as a marker of acute coronary syndrome and myocardial infarction in hospital emergency department, whatever the analytical technique used. (PMID:22044705)
• Measurement of heart-type FABP in patients with acute myocardial infarction shows no improvement for early diagnosis compared with sensitive troponin assay. (PMID:22078394)
• Measurement of urinary proteins is a powerful and non-invasive method to quantify the effect of patent ductus arteriosus on systemic perfusion in preterm infants. (PMID:22222353)
• Common variants of the liver fatty acid binding protein genes 1-4 influence the risk of type 2 diabetes and insulin resistance in Spanish population (PMID:22396741)
• plasma h-fabp was correlated with initial stroke score, and was significantly higher in patients with poor clinical outcome (PMID:22766253)
• H-FABP and GPBB can contribute to early acute myocardial infarction diagnosis and can distinguish acute myocardial infarction from acute coronary syndrome (PMID:22838188)
• study confirmed an association of H-FABP with the pathogenesis of clinical and experimental obesity-related glomerulopathy, and suggests that such a process might be related to podocytes and lipid dysmetabolism (PMID:23029183)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	fabp3	ENSDARG00000023290
mus_musculus	Fabp3	ENSMUSG00000028773
rattus_norvegicus	Fabp3	ENSRNOG00000012879
drosophila_melanogaster	fabp	FBGN0037913
caenorhabditis_elegans		WBGENE00002259
caenorhabditis_elegans		WBGENE00002260

Paralogs (15): RBP2 (ENSG00000114113), RBP1 (ENSG00000114115), RBP5 (ENSG00000139194), CRABP2 (ENSG00000143320), FABP2 (ENSG00000145384), PMP2 (ENSG00000147588), RBP7 (ENSG00000162444), FABP1 (ENSG00000163586), FABP7 (ENSG00000164434), FABP5 (ENSG00000164687), CRABP1 (ENSG00000166426), FABP6 (ENSG00000170231), FABP4 (ENSG00000170323), FABP12 (ENSG00000197416), FABP9 (ENSG00000205186)

Protein

Protein identifiers

Fatty acid-binding protein, heart — P05413 (reviewed: P05413)

Alternative names: Fatty acid-binding protein 3, Heart-type fatty acid-binding protein, Mammary-derived growth inhibitor, Muscle fatty acid-binding protein

All UniProt accessions (4): A0A384MDY5, P05413, S4R371, S4R3A2

UniProt curated annotations — full annotation on UniProt →

Function. FABPs are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters.

Subcellular location. Cytoplasm.

Domain organisation. Forms a beta-barrel structure that accommodates the hydrophobic ligand in its interior.

Similarity. Belongs to the calycin superfamily. Fatty-acid binding protein (FABP) family.

RefSeq proteins (2): NP_001307925, NP_004093* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000463	Fatty_acid-bd	Domain
IPR000566	Lipocln_cytosolic_FA-bd_dom	Domain
IPR012674	Calycin	Homologous_superfamily
IPR031259	ILBP	Family

Pfam: PF00061

UniProt features (29 total): strand 10, modified residue 6, sequence conflict 4, helix 3, binding site 3, initiator methionine 1, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

70 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
7FEZ	X-RAY DIFFRACTION	0.76
9M1X	X-RAY DIFFRACTION	0.8
9M22	X-RAY DIFFRACTION	0.8
7WKB	X-RAY DIFFRACTION	0.81
7FF6	X-RAY DIFFRACTION	0.83
7WF0	X-RAY DIFFRACTION	0.83
7FFK	X-RAY DIFFRACTION	0.84
7WKG	X-RAY DIFFRACTION	0.84
7WCI	X-RAY DIFFRACTION	0.85
4TKB	X-RAY DIFFRACTION	0.86
7FBF	X-RAY DIFFRACTION	0.86
7FDT	X-RAY DIFFRACTION	0.86
7FDU	X-RAY DIFFRACTION	0.86
7WJ1	X-RAY DIFFRACTION	0.86
7X48	X-RAY DIFFRACTION	0.86
4TJZ	X-RAY DIFFRACTION	0.87
4TKJ	X-RAY DIFFRACTION	0.87
7WE5	X-RAY DIFFRACTION	0.87
7WQ7	X-RAY DIFFRACTION	0.87
3WVM	X-RAY DIFFRACTION	0.88
7FFX	X-RAY DIFFRACTION	0.88
7XHM	X-RAY DIFFRACTION	0.88
7XHU	X-RAY DIFFRACTION	0.88
5B28	X-RAY DIFFRACTION	0.9
7VB1	X-RAY DIFFRACTION	0.9
7WDJ	X-RAY DIFFRACTION	0.9
7WOM	X-RAY DIFFRACTION	0.9
7WPG	X-RAY DIFFRACTION	0.9
7V5U	X-RAY DIFFRACTION	0.92
7XBC	X-RAY DIFFRACTION	0.92

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P05413-F1	96.32	0.96

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 127–129; 127–129; 127–129

Post-translational modifications (6): 83, 2, 8, 20, 23, 30

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-163560	Triglyceride catabolism

MSigDB gene sets: 249 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, REACTOME_TRIGLYCERIDE_CATABOLISM, RNGTGGGC_UNKNOWN, GOBP_LIPID_MODIFICATION, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_UP, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_PHOSPHATIDYLCHOLINE_METABOLIC_PROCESS, GOBP_REGULATION_OF_ORGANIC_ACID_TRANSPORT, GOBP_STEROL_HOMEOSTASIS, GOBP_PHOSPHATIDYLCHOLINE_BIOSYNTHETIC_PROCESS, GCANCTGNY_MYOD_Q6, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP

GO Biological Process (14): fatty acid metabolic process (GO:0006631), negative regulation of cell population proliferation (GO:0008285), response to xenobiotic stimulus (GO:0009410), long-chain fatty acid transport (GO:0015909), intracellular lipid transport (GO:0032365), response to insulin (GO:0032868), cholesterol homeostasis (GO:0042632), regulation of fatty acid oxidation (GO:0046320), brown fat cell differentiation (GO:0050873), phospholipid homeostasis (GO:0055091), response to fatty acid (GO:0070542), positive regulation of phospholipid biosynthetic process (GO:0071073), positive regulation of long-chain fatty acid import into cell (GO:0140214), regulation of phosphatidylcholine biosynthetic process (GO:2001245)

GO Molecular Function (8): long-chain fatty acid transmembrane transporter activity (GO:0005324), cytoskeletal protein binding (GO:0008092), long-chain fatty acid binding (GO:0036041), icosatetraenoic acid binding (GO:0050543), oleic acid binding (GO:0070538), fatty acid binding (GO:0005504), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (6): obsolete extracellular space (GO:0005615), nucleus (GO:0005634), cytosol (GO:0005829), sarcoplasm (GO:0016528), extracellular exosome (GO:0070062), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Triglyceride metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of phospholipid biosynthetic process	2
long-chain fatty acid binding	2
binding	2
cytoplasm	2
cellular anatomical structure	2
lipid metabolic process	1
monocarboxylic acid metabolic process	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
response to chemical	1
fatty acid transport	1
lipid transport	1
intracellular transport	1
response to peptide hormone	1
sterol homeostasis	1
regulation of fatty acid metabolic process	1
fatty acid oxidation	1
fat cell differentiation	1
lipid homeostasis	1
response to lipid	1
response to oxygen-containing compound	1
phospholipid biosynthetic process	1
positive regulation of lipid biosynthetic process	1
positive regulation of phospholipid metabolic process	1
long-chain fatty acid import into cell	1
regulation of long-chain fatty acid import into cell	1
positive regulation of fatty acid transport	1
phosphatidylcholine biosynthetic process	1
regulation of phosphatidylcholine metabolic process	1
fatty acid transmembrane transporter activity	1
long-chain fatty acid transport	1
protein binding	1
fatty acid binding	1
lipid binding	1
monocarboxylic acid binding	1
intracellular membrane-bounded organelle	1
extracellular vesicle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1760 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FABP3	GOT2	P00505	946
FABP3	FABP1	P07148	927
FABP3	FAAH	O00519	826
FABP3	CD36	P16671	775
FABP3	SCARB2	Q14108	748
FABP3	SCARB1	Q8WTV0	746
FABP3	TNNI3	P19429	701
FABP3	SLC27A6	Q9Y2P4	677
FABP3	ACAA2	P42765	668
FABP3	MB	P02144	664
FABP3	FABP6	P51161	664
FABP3	ACACB	O00763	654
FABP3	ACSL1	P33121	629
FABP3	FASN	P49327	626
FABP3	ALB	P02768	614

IntAct

37 interactions, top by confidence:

A	B	Type	Score
FABP3	NUP62	psi-mi:“MI:0915”(physical association)	0.780
NUP62	FABP3	psi-mi:“MI:0915”(physical association)	0.780
COPS6	RHOBTB1	psi-mi:“MI:0914”(association)	0.730
SHTN1	FABP3	psi-mi:“MI:0915”(physical association)	0.560
FABP3	SHTN1	psi-mi:“MI:0915”(physical association)	0.560
PLXNA4	CRYZL1	psi-mi:“MI:0914”(association)	0.560
CTLA4	B4GALT5	psi-mi:“MI:0914”(association)	0.530
FABP3	ITGB1	psi-mi:“MI:0915”(physical association)	0.470
ITGB1	FABP3	psi-mi:“MI:2364”(proximity)	0.470
ITGA2	FABP3	psi-mi:“MI:0407”(direct interaction)	0.440
FABP3	ITGA1	psi-mi:“MI:0407”(direct interaction)	0.440
Xpo1	XPO1	psi-mi:“MI:0915”(physical association)	0.400
FABP3	TNNI3K	psi-mi:“MI:0915”(physical association)	0.370
PPP1CA	ACO2	psi-mi:“MI:0914”(association)	0.350
PLK1	ERCC6L	psi-mi:“MI:0914”(association)	0.350
NME5	INPPL1	psi-mi:“MI:0914”(association)	0.350
ADSS1	FABP3	psi-mi:“MI:0914”(association)	0.350
MFGE8	MYH7B	psi-mi:“MI:0914”(association)	0.350
MRPS23	MYH7B	psi-mi:“MI:0914”(association)	0.350
OLFM4	SPINT1	psi-mi:“MI:0914”(association)	0.350
RARS2	C3	psi-mi:“MI:0914”(association)	0.350
SSRP1	FABP3	psi-mi:“MI:0914”(association)	0.350
TTC4	MYH7B	psi-mi:“MI:0914”(association)	0.350
FABP3	ITGA5	psi-mi:“MI:2364”(proximity)	0.270
FABP3	ITGB4	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (35): NUP62 (Two-hybrid), KIAA1598 (Two-hybrid), FABP3 (Affinity Capture-MS), FABP3 (Co-fractionation), FABP3 (Co-fractionation), FABP3 (Co-fractionation), FABP3 (Co-fractionation), FKBP1A (Co-fractionation), NUP62 (Two-hybrid), FABP3 (Two-hybrid), ALDH4A1 (Co-fractionation), LYPLAL1 (Co-fractionation), IDH2 (Co-fractionation), HMGCL (Co-fractionation), DSTN (Co-fractionation)

ESM2 similar proteins: A0A0K0MJ13, A0A0K0MJN3, A6YLM6, C4N147, O01812, O01814, O02772, O08716, O13008, O15540, O45035, O97788, P02689, P02690, P02691, P04117, P05413, P06768, P07483, P0C6G6, P10790, P11404, P15090, P24526, P29498, P41496, P41509, P48035, P50120, P50121, P51880, P55051, P55052, P55053, P70623, P80049, P86412, Q01469, Q02970, Q05423

Diamond homologs: A0A0K0MJ13, A0A0K0MJN3, A6NFH5, A6YLM6, A8MUU1, B7SUM8, C4N147, O01812, O01814, O02323, O02324, O02772, O08716, O13008, O15540, O42386, O45035, O76821, O97788, P02689, P02690, P02691, P02694, P02696, P04117, P05413, P06768, P07148, P07483, P09455, P0C6G6, P10790, P11404, P12710, P15090, P22935, P24526, P29373, P29498, P29762

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
FABP3	“up-regulates quantity”	“Fatty acid”	relocalization
TFEB	“up-regulates quantity by expression”	FABP3	“transcriptional regulation”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 34 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
L1CAM interactions	5	21.5×	2e-04
Extracellular matrix organization	5	11.3×	2e-03
Axon guidance	5	8.1×	8e-03
Nervous system development	5	7.7×	9e-03

GO biological processes:

GO term	Partners	Fold	FDR
cell-matrix adhesion	5	25.6×	1e-04
integrin-mediated signaling pathway	5	25.1×	1e-04
cell-cell adhesion	5	15.9×	8e-04
cell adhesion	7	8.2×	9e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

41 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	26
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

951 predictions. Top by Δscore:

Variant	Effect	Δscore
1:31367387:TCTTA:T	donor_loss	1.0000
1:31367388:CTTAC:C	donor_loss	1.0000
1:31367389:TTA:T	donor_loss	1.0000
1:31367390:TACC:T	donor_loss	1.0000
1:31367392:C:T	donor_loss	1.0000
1:31367490:ATGGA:A	acceptor_gain	1.0000
1:31367491:TGGA:T	acceptor_gain	1.0000
1:31367492:GGA:G	acceptor_gain	1.0000
1:31367493:GA:G	acceptor_gain	1.0000
1:31367495:C:CC	acceptor_gain	1.0000
1:31367497:G:C	acceptor_gain	1.0000
1:31369380:CTTA:C	donor_loss	1.0000
1:31369381:TTA:T	donor_loss	1.0000
1:31369382:TA:T	donor_loss	1.0000
1:31369555:CAC:C	acceptor_gain	1.0000
1:31372938:TCA:T	donor_loss	1.0000
1:31372939:CAC:C	donor_loss	1.0000
1:31372940:A:AC	donor_gain	1.0000
1:31372940:A:AG	donor_loss	1.0000
1:31372941:C:CC	donor_gain	1.0000
1:31372941:C:G	donor_loss	1.0000
1:31364187:GGA:G	donor_gain	0.9900
1:31364188:GAG:G	donor_gain	0.9900
1:31365936:GTGT:G	acceptor_gain	0.9900
1:31365937:TGT:T	acceptor_gain	0.9900
1:31365940:C:CC	acceptor_gain	0.9900
1:31367386:ATCTT:A	donor_loss	0.9900
1:31367391:A:AC	donor_gain	0.9900
1:31367392:C:CC	donor_gain	0.9900
1:31367492:GGACT:G	acceptor_loss	0.9900

AlphaMissense

877 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:31369394:C:A	R79S	0.997
1:31369394:C:G	R79S	0.997
1:31365908:C:G	R127P	0.996
1:31365913:G:C	C125W	0.996
1:31367394:A:G	L116P	0.996
1:31367421:C:G	R107P	0.996
1:31369463:G:C	S56R	0.996
1:31369463:G:T	S56R	0.996
1:31369465:T:G	S56R	0.996
1:31369530:G:T	A34D	0.996
1:31367494:A:G	S83P	0.995
1:31369395:C:A	R79M	0.995
1:31372990:A:G	W9R	0.995
1:31372990:A:T	W9R	0.995
1:31365915:A:G	C125R	0.994
1:31367400:A:G	L114P	0.994
1:31367493:G:A	S83F	0.994
1:31369395:C:G	R79T	0.994
1:31369538:C:A	R31S	0.994
1:31369538:C:G	R31S	0.994
1:31369545:G:T	A29D	0.994
1:31369539:C:G	R31T	0.993
1:31365909:G:T	R127S	0.992
1:31369418:G:C	F71L	0.992
1:31369418:G:T	F71L	0.992
1:31369420:A:G	F71L	0.992
1:31369533:A:T	V33E	0.992
1:31369539:C:A	R31M	0.992
1:31372988:C:A	W9C	0.992
1:31372988:C:G	W9C	0.992

dbSNP variants (sampled 300 via entrez): RS1000059229 (1:31371662 C>T), RS1000127157 (1:31369651 G>A), RS1000369542 (1:31371903 C>T), RS1000604895 (1:31364824 C>T), RS1000711538 (1:31359242 G>A), RS1001089145 (1:31361771 T>G), RS1001479097 (1:31366074 G>A,C), RS1001910932 (1:31374931 A>G), RS1002025491 (1:31374585 G>T), RS1002137351 (1:31373118 A>G,T), RS1002266267 (1:31367761 G>A), RS1002273691 (1:31370302 C>T), RS1002330085 (1:31367080 C>T), RS1002640039 (1:31359537 A>AAT), RS1002674127 (1:31366071 T>C)

Disease associations

OMIM: gene MIM:134651 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST001874_1	Alcohol dependence	3.000000e-08
GCST005951_36	Body mass index	9.000000e-10
GCST006186_9	Systolic blood pressure x smoking status (current vs non-current) interaction (1df test)	2.000000e-07
GCST006193_8	Diastolic blood pressure x smoking status (current vs non-current) interaction (2df test)	8.000000e-06
GCST006195_95	Systolic blood pressure x smoking status (current vs non-current) interaction (2df test)	8.000000e-10

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0006335	systolic blood pressure
EFO:0006527	smoking status measurement
EFO:0006336	diastolic blood pressure

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3344 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 323,195 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL267476	LINOLEIC ACID	2	323,195

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Fatty acid-binding proteins

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
compound 13 [PMID: 17502136]	Inhibition	8.4	pKi

Binding affinities (BindingDB)

1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL5543014	KI	24 nM

ChEMBL bioactivities

163 potent at pChembl≥5 of 194 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.70	Kd	0.2	nM	CHEMBL3122088
9.43	Ki	0.37	nM	CHEMBL5564812
8.89	Ki	1.29	nM	CHEMBL5571195
8.66	Ki	2.19	nM	CHEMBL5565638
8.56	Kd	2.76	nM	CHEMBL3122087
8.44	Kd	3.6	nM	CHEMBL1235508
8.40	Ki	4	nM	CHEMBL247298
8.40	Ki	4	nM	CHEMBL5575316
8.29	Ki	5.18	nM	CHEMBL5564125
8.13	Ki	7.46	nM	CHEMBL5563843
8.12	Ki	7.51	nM	CHEMBL5590346
7.82	Ki	15.03	nM	CHEMBL5563556
7.81	Ki	15.37	nM	CHEMBL5573363
7.62	Ki	24	nM	CHEMBL5543014
7.50	Ki	32	nM	CHEMBL116533
7.47	IC50	34	nM	CHEMBL460750
7.28	IC50	52	nM	CHEMBL5878164
7.13	Kd	74	nM	CHEMBL3122153
7.11	IC50	77	nM	CHEMBL5555714
7.10	Ki	80	nM	CHEMBL5912035
7.05	Ki	90	nM	CHEMBL1738980
7.03	Ki	93	nM	CHEMBL1738980
7.00	Ki	100	nM	CHEMBL3950316
7.00	Ki	100	nM	CHEMBL5795509
7.00	Ki	100	nM	CHEMBL4283759
6.96	Ki	110	nM	CHEMBL394440
6.82	Ki	150	nM	CHEMBL5287034
6.80	Kd	159	nM	CHEMBL3122151
6.80	Ki	160	nM	CHEMBL4290535
6.77	Ki	170	nM	CHEMBL4287414
6.75	Ki	180	nM	CHEMBL4278244
6.72	Ki	190	nM	CHEMBL4276759
6.66	Ki	220	nM	CHEMBL247529
6.64	IC50	230	nM	CHEMBL3400905
6.60	Ki	250	nM	CHEMBL247920
6.55	IC50	280	nM	CHEMBL5770423
6.51	Ki	310	nM	CHEMBL4293382
6.46	Ki	350	nM	CHEMBL4644782
6.44	Ki	360	nM	CHEMBL248120
6.43	Ki	370	nM	CHEMBL6059370
6.42	Ki	380	nM	CHEMBL3947458
6.41	Ki	390	nM	CHEMBL3947458
6.41	Kd	386	nM	CHEMBL5555714
6.40	Kd	401	nM	CHEMBL3122152
6.40	Ki	400	nM	CHEMBL3971182
6.40	Ki	400	nM	CHEMBL4284051
6.38	Kd	414	nM	CHEMBL5976044
6.38	Ki	420	nM	CHEMBL5778826
6.38	Ki	420	nM	CHEMBL4287117
6.35	IC50	450	nM	CHEMBL3400157

PubChem BioAssay actives

130 with measured affinity, of 287 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
potassium (9Z,12Z)-octadeca-9,12-dienoate	1072809: Binding affinity to human FABP3 expressed in Escherichia coli BL21 (DE3) in DMPC liposomes by surface plasmon resonance analysis	kd	0.0002	uM
2-(3-chloro-2-phenylanilino)-5-fluorobenzoic acid	2096494: Displacement of 1,8-ANS from N-terminal 6His-tagged full length FABP3 (unknown origin) expressed in Escherichia coli ER2566 assessed as inhibition constant preincubated with compound for 10 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based analysis	ki	0.0004	uM
5-chloro-2-(3-chloro-2-phenylanilino)benzoic acid	2096494: Displacement of 1,8-ANS from N-terminal 6His-tagged full length FABP3 (unknown origin) expressed in Escherichia coli ER2566 assessed as inhibition constant preincubated with compound for 10 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based analysis	ki	0.0013	uM
2-(3-chloro-2-phenylanilino)-5-methoxybenzoic acid	2096494: Displacement of 1,8-ANS from N-terminal 6His-tagged full length FABP3 (unknown origin) expressed in Escherichia coli ER2566 assessed as inhibition constant preincubated with compound for 10 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based analysis	ki	0.0022	uM
potassium (9Z,12Z,15Z)-octadeca-9,12,15-trienoate	1072809: Binding affinity to human FABP3 expressed in Escherichia coli BL21 (DE3) in DMPC liposomes by surface plasmon resonance analysis	kd	0.0028	uM
2-[[(2R)-2,3-di(tetradecanoyloxy)propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium	1072813: Binding affinity to human FABP3 expressed in Escherichia coli BL21 (DE3) at 60 uM by surface plasmon resonance analysis	kd	0.0036	uM
6-(3-chloro-2-phenylanilino)-3-fluoro-2-methylbenzoic acid	2096494: Displacement of 1,8-ANS from N-terminal 6His-tagged full length FABP3 (unknown origin) expressed in Escherichia coli ER2566 assessed as inhibition constant preincubated with compound for 10 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based analysis	ki	0.0040	uM
2,3-bis[(2,4-dichloro-3-tritiophenyl)methoxy]benzoic acid	307908: Displacement of 1,8-ANS from mFABP by fluorescence based-assay	ki	0.0040	uM
2-chloro-6-(3-chloro-2-phenylanilino)benzoic acid	2096494: Displacement of 1,8-ANS from N-terminal 6His-tagged full length FABP3 (unknown origin) expressed in Escherichia coli ER2566 assessed as inhibition constant preincubated with compound for 10 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based analysis	ki	0.0052	uM
6-[3-chloro-2-(2,3-dihydro-1-benzofuran-5-yl)anilino]-3-fluoro-2-methylbenzoic acid	2096494: Displacement of 1,8-ANS from N-terminal 6His-tagged full length FABP3 (unknown origin) expressed in Escherichia coli ER2566 assessed as inhibition constant preincubated with compound for 10 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based analysis	ki	0.0075	uM
2-(3-chloro-2-phenylanilino)-5-methylbenzoic acid	2096494: Displacement of 1,8-ANS from N-terminal 6His-tagged full length FABP3 (unknown origin) expressed in Escherichia coli ER2566 assessed as inhibition constant preincubated with compound for 10 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based analysis	ki	0.0075	uM
2-(3-chloro-2-phenylanilino)-6-methylbenzoic acid	2096494: Displacement of 1,8-ANS from N-terminal 6His-tagged full length FABP3 (unknown origin) expressed in Escherichia coli ER2566 assessed as inhibition constant preincubated with compound for 10 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based analysis	ki	0.0150	uM
2-[3-chloro-2-(2,3-dihydro-1-benzofuran-5-yl)anilino]-6-methylbenzoic acid	2096494: Displacement of 1,8-ANS from N-terminal 6His-tagged full length FABP3 (unknown origin) expressed in Escherichia coli ER2566 assessed as inhibition constant preincubated with compound for 10 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based analysis	ki	0.0154	uM
4-[4-fluoro-2-[1-phenyl-5-[2-(trifluoromethyl)phenyl]pyrazol-3-yl]phenoxy]butanoic acid	2082680: Binding affinity to FABP3 (unknown origin) assessed as inhibition constant	ki	0.0240	uM
5-[2-(4,5-diphenyl-1,3-oxazol-2-yl)phenoxy]pentanoic acid	307908: Displacement of 1,8-ANS from mFABP by fluorescence based-assay	ki	0.0320	uM
5-[[2-(trifluoromethyl)phenyl]methyl]-7,8,9,10-tetrahydro-6H-cyclohepta[b]indole-4-carboxylic acid	418916: Inhibition of human H-FABP by scintillation proximity assay	ic50	0.0340	uM
potassium (E)-octadec-9-enoate	1072811: Binding affinity to human FABP3 expressed in Escherichia coli BL21 (DE3) at 10 uM in DMPC liposomes by surface plasmon resonance analysis	kd	0.0740	uM
6-chloro-2-methyl-4-phenylquinoline-3-carboxylic acid	1949365: Inhibition of FABP3 (unknown origin) assessed as inhibition constant	ki	0.0900	uM
6-chloro-8-methyl-4-phenyl-2-piperidin-1-ylquinoline-3-carboxylic acid	1322081: Displacement of Bodipy-labeled fatty acid from human FABP3 after 30 mins by TR-FRET assay	ki	0.1000	uM
3-[2-(5-ethyl-3,4-diphenylpyrazol-1-yl)phenyl]benzoic acid	307908: Displacement of 1,8-ANS from mFABP by fluorescence based-assay	ki	0.1100	uM
6-chloro-2-ethyl-4-phenylquinoline-3-carboxylic acid	1949365: Inhibition of FABP3 (unknown origin) assessed as inhibition constant	ki	0.1500	uM
potassium (Z)-octadec-9-enoate	1072811: Binding affinity to human FABP3 expressed in Escherichia coli BL21 (DE3) at 10 uM in DMPC liposomes by surface plasmon resonance analysis	kd	0.1590	uM
2-[3-[2-(3-ethyl-4,5-diphenylfuran-2-yl)phenyl]phenoxy]acetic acid	307908: Displacement of 1,8-ANS from mFABP by fluorescence based-assay	ki	0.2200	uM
2,4,6-tri(propan-2-yl)benzoic acid	1192390: Inhibition of FABP4 (unknown origin) relative to linoleic acid	ic50	0.2300	uM
2-[3-[2-(5-ethyl-3,4-diphenylpyrazol-1-yl)phenyl]phenoxy]acetic acid	307908: Displacement of 1,8-ANS from mFABP by fluorescence based-assay	ki	0.2500	uM
2-[2-(1-benzofuran-5-yl)-3-chloroanilino]benzoic acid	1648408: Displacement of 1,8-ANS from recombinant human 6His-tagged FABP3 expressed in Escherichia coli BL21 DE3 incubated for 15 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based assay	ki	0.3500	uM
2-[3-[2-(5-ethyl-3,4-diphenylpyrazol-1-yl)phenyl]phenyl]-2-hydroxyacetic acid	307908: Displacement of 1,8-ANS from mFABP by fluorescence based-assay	ki	0.3600	uM
6-chloro-4-phenyl-2-propan-2-ylquinoline-3-carboxylic acid	1949365: Inhibition of FABP3 (unknown origin) assessed as inhibition constant	ki	0.3800	uM
trans-(2S,4S)-2,4-bis(2-methoxyphenyl)-3-[(1R,2S)-2-phenylcyclohexyl]oxycarbonylcyclobutane-1-carboxylic acid	1404705: Displacement of DAUDA from recombinant human N-terminal His-tagged FABP3 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.4000	uM
6,8-dichloro-4-phenyl-2-piperidin-1-ylquinoline-3-carboxylic acid	1322081: Displacement of Bodipy-labeled fatty acid from human FABP3 after 30 mins by TR-FRET assay	ki	0.4000	uM
potassium (Z)-octadec-6-enoate	1072811: Binding affinity to human FABP3 expressed in Escherichia coli BL21 (DE3) at 10 uM in DMPC liposomes by surface plasmon resonance analysis	kd	0.4010	uM
2,4,6-tri(propan-2-yl)benzenesulfonic acid	1192390: Inhibition of FABP4 (unknown origin) relative to linoleic acid	ic50	0.4500	uM
5-[(3-chloro-2-methylphenoxy)methyl]-2-phenyl-1H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one	1958770: Binding affinity to human FABP3 expressed in Escherichia coli assessed as degree of fluorescent shift by temperature-dependent fluorescence thermal shift assay	kd	0.5200	uM
6-chloro-5-[(3-chloro-2-cyclopropylphenoxy)methyl]-2-phenyl-1H-[1,2,4]triazolo[1,5-a]pyrimidin-7-one	1958770: Binding affinity to human FABP3 expressed in Escherichia coli assessed as degree of fluorescent shift by temperature-dependent fluorescence thermal shift assay	kd	0.5600	uM
4-carbazol-9-ylbutanoic acid	1958761: Inhibition of FABP3 (unknown origin) by fluorescence polarization assay	ic50	0.6000	uM
trans-(2S,4S)-2,4-diphenyl-3-[(1R,2S)-2-phenylcyclohexyl]oxycarbonylcyclobutane-1-carboxylic acid	1404705: Displacement of DAUDA from recombinant human N-terminal His-tagged FABP3 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.6400	uM
9-[(2-fluorophenyl)methyl]-5,6,7,8-tetrahydrocarbazole-1-carboxylic acid	418914: Inhibition of human H-FABP by fluorescence polarization assay	ic50	0.6800	uM
trans-(2S,4S)-2,4-bis(2-methoxyphenyl)-3-naphthalen-1-yloxycarbonylcyclobutane-1-carboxylic acid	1404705: Displacement of DAUDA from recombinant human N-terminal His-tagged FABP3 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.6900	uM
4-[2-[1-(3-chlorophenyl)-5-phenylpyrazol-3-yl]phenoxy]butanoic acid	733214: Inhibition of human FABP3 by 8-anilino-1-naphthalenesulfonic acid based fluorescence displacement assay	ic50	0.6950	uM
trans-(2S,4S)-2,4-diphenyl-3-(2-phenylphenoxy)carbonylcyclobutane-1-carboxylic acid	1404705: Displacement of DAUDA from recombinant human N-terminal His-tagged FABP3 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.7000	uM
4-[2-[1-(4-bromophenyl)-5-phenylpyrazol-3-yl]phenoxy]butanoic acid	733214: Inhibition of human FABP3 by 8-anilino-1-naphthalenesulfonic acid based fluorescence displacement assay	ic50	0.7330	uM
4-[2-[1-(4-chlorophenyl)-5-phenylpyrazol-3-yl]phenoxy]butanoic acid	733214: Inhibition of human FABP3 by 8-anilino-1-naphthalenesulfonic acid based fluorescence displacement assay	ic50	0.7330	uM
2-[3-chloro-2-(1H-indazol-5-yl)anilino]benzoic acid	1648408: Displacement of 1,8-ANS from recombinant human 6His-tagged FABP3 expressed in Escherichia coli BL21 DE3 incubated for 15 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based assay	ki	0.7400	uM
4-[2-[5-phenyl-1-(4-propan-2-ylphenyl)pyrazol-3-yl]phenoxy]butanoic acid	733214: Inhibition of human FABP3 by 8-anilino-1-naphthalenesulfonic acid based fluorescence displacement assay	ic50	0.7870	uM
trans-(2S,4S)-2,4-diphenyl-3-[(1S,2R)-2-phenylcyclohexyl]oxycarbonylcyclobutane-1-carboxylic acid	1404705: Displacement of DAUDA from recombinant human N-terminal His-tagged FABP3 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	0.8200	uM
2-[2-(1,3-benzodioxol-5-yl)-3-chloroanilino]benzoic acid	1648408: Displacement of 1,8-ANS from recombinant human 6His-tagged FABP3 expressed in Escherichia coli BL21 DE3 incubated for 15 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based assay	ki	0.8600	uM
2-[3-chloro-2-(2,3-dihydro-1-benzofuran-5-yl)anilino]benzoic acid	2009560: Displacement of 1,8-ANS from FABP3 (unknown origin) assessed as inhibition constant by fluorescence based analysis	ki	0.9200	uM
2-(3-chloro-2-phenylanilino)benzoic acid	1648408: Displacement of 1,8-ANS from recombinant human 6His-tagged FABP3 expressed in Escherichia coli BL21 DE3 incubated for 15 mins followed by 1,8-ANS addition and measured after 3 mins by fluorescence based assay	ki	1.0000	uM
(9Z,12Z)-octadeca-9,12-dienoic acid	1192390: Inhibition of FABP4 (unknown origin) relative to linoleic acid	ic50	1.0000	uM
trans-(2S,4S)-2,4-bis(4-hydroxy-3-methoxyphenyl)-3-naphthalen-1-yloxycarbonylcyclobutane-1-carboxylic acid	1404705: Displacement of DAUDA from recombinant human N-terminal His-tagged FABP3 expressed in Escherichia coli BL21(DE3) after 20 mins by fluorescence assay	ki	1.0600	uM

CTD chemical–gene interactions

65 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, decreases expression	4
Valproic Acid	increases expression	4
sodium arsenite	decreases expression, affects splicing, increases expression	3
Oxygen	affects cotreatment, decreases reaction, increases expression, decreases expression	3
nickel sulfate	decreases expression, increases expression	2
entinostat	increases expression, affects cotreatment	2
bisphenol S	increases expression	2
Troglitazone	decreases expression, increases expression	2
Vorinostat	affects cotreatment, increases expression, decreases expression	2
Panobinostat	increases expression, affects cotreatment	2
aristolochic acid I	increases expression	1
methylmercuric chloride	increases expression	1
notexin	increases secretion	1
deoxynivalenol	decreases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
mono-(2-ethylhexyl)phthalate	increases expression	1
sulforaphane	decreases expression	1
cobaltous chloride	decreases expression	1
potassium chromate(VI)	increases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
Omacor	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
belinostat	affects cotreatment, increases expression	1
bisphenol B	increases expression	1
quinocetone	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1

ChEMBL screening assays

45 unique, capped per target: 39 binding, 5 admet, 1 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1102421	Binding	Displacement of radiolabeled 1-anilinonaphthalene 8-sulfonic acid from HFABP expressed in Escherichia coli BL21 (DE3) by fluorescence spectrophotometry	Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins. — J Med Chem
CHEMBL4271664	ADMET	Inhibition of FABP3 (unknown origin)	From hit to lead: Structure-based discovery of naphthalene-1-sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4. — Eur J Med Chem
CHEMBL5538252	Toxicity	Displacement of 1,8-ANS from N-terminal 6His-tagged full length FABP3 (unknown origin) expressed in Escherichia coli ER2566 assessed as inhibition constant preincubated with compound for 10 mins followed by 1,8-ANS addition and measured aft	Structure-based design of potent FABP4 inhibitors with high selectivity against FABP3. — Eur J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.